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Background: Patients with symptomatic peripheral artery disease (PAD) are at high risk of
ischemic events. However, data about predictors of this risk are limited.
Hypothesis: We analyzed baseline characteristics and 4-year follow-up of patients enrolled in
the international REduction of Atherothrombosis for Continued Health (REACH) Registry with
symptomatic PAD and no history of stroke/transient ischemic attack to describe annual rates
of recurrent ischemic events globally and geographically.
Methods: The primary outcome was systemic ischemic events (composite of cardiovascular
death, myocardial infarction, or stroke) at 4 years. The secondary outcome was limb ischemic
events (composite of lower limb amputation, peripheral bypass graft, and percutaneous inter-
vention for PAD) at 2 years. Multivariate analysis identified risk factors associated with recur-
rent ischemic events.
Results: The primary endpoint rate reached 4.7% during the first year and increased continu-
ously (by 4%–5% each year) to 17.6% by year 4, driven mainly by cardiovascular mortality
(11.1% at year 4). Japan experienced lower adjusted ischemic rates (P < 0.01) vs North America.
Renal impairment (P < 0.01), congestive heart failure (P < 0.01), history of diabetes (P < 0.01),
history of myocardial infarction (P = 0.01), vascular disease (single or poly, P < 0.01), and older
age (P < 0.01) were associated with increased risk of systemic ischemic events, whereas statin
use was associated with lower risk (P = 0.03). The limb ischemic event rate was 5.7% at
2 years.
Conclusions: Four-year systemic ischemic risk in patients with PAD and no history of stroke or
transient ischemic attack remains high, and was mainly driven by cardiovascular mortality.
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1 | INTRODUCTION
Over 202 million people worldwide were estimated to be living with
peripheral artery disease (PAD) in 2010, with estimated prevalence
rates of 9% in North America and 11% in Europe.1 The spectrum of
PAD includes acute and chronic limb ischemia, asymptomatic PAD,
claudication, and critical limb ischemia.2,3 PAD is a strong predictor of
myocardial infarction (MI), stroke, and death from vascular causes,4,5
with an annual incidence of approximately 5% for the composite end-
point of stroke, MI, and death in patients with PAD over 1 year.6
Understanding the current trends in PAD prevalence and risk factors
is critical in guiding preventive strategies to reduce the burden of
PAD. However, contemporary, real-world data regarding patient pro-
files, treatment patterns, and cardiovascular (CV) risks for PAD
patients beyond 1 year are insufficient, and are often limited to a sin-
gle geographic region.
To address gaps in evidence for characterization of longer-term
ischemic risk in PAD patients, we analyzed 4-year data from the
REduction of Atherothrombosis for Continued Health (REACH) Regis-
try, an international registry of atherothrombosis7–9 in patients with
symptomatic PAD with no history of stroke or transient ischemic
attack (TIA), focusing on both systemic (MI, stroke, and CV death)
and limb ischemic complications (lower limb amputation, peripheral
bypass graft, and percutaneous intervention for PAD). Patients with
prior stoke or TIA were excluded, because the risk and benefit bal-
ance of antithrombotic agents in this population is specific and has
been previously published as a separate analysis.10 The objectives of
the present study were to (1) describe annual rates of systemic ische-
mic events (MI, stroke, and CV death) over 4 years globally and by
geographic region, and to identify associated risk factors; and (2) to
describe limb ischemic event rates (a composite of lower limb ampu-
tation, peripheral bypass graft, and percutaneous intervention for
PAD) over 2 years.
2 | METHODS
2.1 | Population
The design, methods, and main results of the REACH Registry, an
international, prospective, observational study, have been previously
described.7,11 Briefly, from December 2003 to June 2004, consecu-
tive outpatients ages 45 years or older with established coronary
artery disease (CAD), cerebrovascular disease, or PAD, or with at
least 3 atherothrombotic risk factors were enrolled. Documented
PAD was defined as 1 or more of the following: current intermit-
tent claudication with ankle-brachial index of less than 0.9 or a his-
tory of intermittent claudication together with a previous and
related intervention such as angioplasty, stenting, atherectomy,
peripheral arterial bypass graft, or other vascular intervention
including amputation. Documented CAD was defined as 1 or more
of the following: stable angina with documented CAD, history of
unstable angina with documented CAD, history of percutaneous
coronary intervention, history of coronary artery bypass graft sur-
gery, or previous MI.
Data were collated centrally using standardized case report
forms. The initial follow-up period was 2 years, but centers were
invited to participate in a 2-year extension. Only patients with PAD
and no history of stroke or TIA were included in the present analysis.
Signed informed consent was obtained from all patients, and the
institutional review board in each country approved the protocol.
The population was divided into 7 geographical regions: North
America, including Canada and United States of America; Latin Amer-
ica, including Brazil, Chile, and Mexico; Western Europe, including
patients from Austria, Belgium, Finland, France, Germany, Greece, the
Netherlands, Portugal, Spain, Switzerland, and the United Kingdom;
Eastern Europe, including patients from Hungary, Romania, Russia,
and Ukraine; Middle East including patients from Israel and the
United Arab Emirates; Asia including patients from China, Taiwan,
Hong Kong, Malaysia, the Philippines, and Thailand; and Japan.
2.2 | Outcomes
Following enrollment, detailed baseline characteristics, treatment, and
outcomes were collected annually. Endpoints were not adjudicated
and were based on physician report at the time of follow-up. We
analyzed 3 systemic ischemic outcomes over 4 years: nonfatal MI,
nonfatal stroke, and CV death; and 3 limb ischemic outcomes at
2 years: lower limb amputation, peripheral bypass graft, and percuta-
neous intervention for PAD. Limb ischemic outcomes were not adju-
dicated, but were tracked on a declarative basis at the end of follow-
up. Consequently, due to missing data at 4 years, this endpoint was
analyzed at 2 years.
The primary outcome was the composite of the 3 systemic ische-
mic events, and the secondary outcome was the composite of the
3 limb ischemic events. Other secondary outcomes of interest
included CV death, MI, and stroke analyzed separately, as well as CV
hospitalization.
Stroke was verified by a neurologist consultation or hospital
records. CV death was defined as any MI or stroke followed by death
in the next 28 days regardless of the cause, death from pulmonary
embolism, heart failure, death following vascular surgery, death fol-
lowing a visceral or limb infarction, or any sudden death unless
proven to be non-CV by autopsy.
2.3 | Statistical analysis
Descriptive statistics, including frequencies and percentages for cate-
gorical variables, and mean and standard deviation for continuous
variables were calculated to describe the patients’ baseline character-
istics, medical history, and treatment patterns using the overall study
population. Kaplan-Meier estimates were used to assess cumulative
incidence rates at each year of follow-up. Patients from each region
were also investigated as subgroups.
The exact date of each systemic ischemic event was systemati-
cally collected, whereas limb events were collected on a yearly basis
during follow-up visits, precluding assignment of a precise date.
Therefore, systemic and limb ischemic outcomes were analyzed
separately.
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The risks of CV events in each geographic region were estimated
by Cox proportional hazards models adjusted for the REACH risk
score predicting CV events,12 after exclusion of the geographic items
of the score. Multivariate Cox regression models were used to assess
the factors associated with CV risk in the study population. Univari-
ate models were first built to assess the impact of each individual var-
iable on CV outcomes. A set of variables was then selected according
to their statistical significance in the univariate model (P ≤ 0.10), clini-
cal significance, and nonredundancy with other variables in the
model, and was introduced into the multivariate models. In addition,
clinically relevant factors with plausible clinical association with ische-
mic events were forced into the multivariate Cox regression model.
Data were processed using the SAS software package (version
9.3; SAS Institute, Cary, NC). Elbez Yedid had access to all of the data
in the study and takes responsibility for its integrity and the data
analysis.
3 | RESULTS
Overall, 65 531 patients were initially enrolled in the REACH Registry
in 44 countries and 5587 centers. Of these, 8322 had a history of
symptomatic PAD, of whom 6005 (76.7%, 95% confidence interval
[CI]: 75.8%-77.6%) had no history of stroke or TIA and constituted
the study population for this analysis. Two-year follow-up was com-
pleted in 5336 (88.9%) patients, and the 4-year follow-up was com-
pleted in 2998 (49.9%) patients. The population included 1785
(29.7%) patients from North America, 162 (2.7%) from Latin America,
2702 (45%) from Western Europe, 441 (7.3%) from Eastern Europe,
38 (0.6%) from the Middle East, 213 (3.6%) from Asia, and 473 (7.9%)
from Japan.
3.1 | Baseline characteristics
In the overall population, the mean age was 70  10 years, and
69.2% were men. At enrollment, 47.3% had diabetes mellitus, 66.2%
had hypercholesterolemia, 89.1% had hypertension, 20.9% were cur-
rent smokers, and 18.7% were overweight/obese. Important differ-
ences in baseline characteristics were observed according to
geographic region (Table 1).
3.2 | Systemic ischemic events
The 2-year rate of systemic ischemic events (CV death, MI, or stroke)
in the overall population was 9.1%, and the 4-year rate was 17.6%
(Figure 1). The rate of systemic ischemic events increased cumula-
tively by approximately 4% to 5% for each year of follow-up
(Figure 1). The primary outcome was mainly driven by CV death,
accounting for half of the composite outcome, with an increase of
~3% each year (2.7%, 5.2%, 8.2%, 11.1%) (Figure 2A). Nonfatal MI
increased from 1.3% to 2.4% to 3.3% to 4.4% (Figure 2B) with each
additional year of follow-up, and nonfatal stroke from 1.0% to 2.3%
to 3.3 to 4.5% (Figure 2C). Similarly, the rate of CV hospitalization
increased cumulatively over the 4 years of follow-up from 17.8% the
first year to 26.3% to 33.4% and 38.3% the fourth year (Figure 2D).
3.3 | According to geographic region
Compared with North America, patients who were enrolled in Eastern
Europe (hazard ratio [HR] = 0.73, 95% CI: 0.55-0.98, P = 0.03), West-
ern Europe (HR = 0.83, 95% CI: 0.70-0.98, P = 0.02), or Japan
(HR = 0.53, 95% CI: 0.41-0.67, P < 0.01) had lower crude 4-year
cumulative event rates (Figure 3). After adjusting for baseline charac-
teristics, the only persistent difference was for Japanese patients,
who experienced fewer ischemic events (HR = 0.61, 95% CI: 0.45-
0.83, P < 0.01) (Figure 3). Complete analysis of outcomes according
to geographic region are shown in Figure 3.
3.4 | Risk factors associated with systemic ischemic
events
Renal impairment (HR = 2.98, 95% CI: 1.69-3.12, P < 0.01), heart fail-
ure (HR = 1.65, 95% CI: 1.34-2.02, P < 0.01), history of diabetes
(HR = 1.50, 95% CI: 1.26-1.78, P < 0.01), history of MI (HR = 1.33,
95% CI: 1.07-1.64, P = 0.01), vascular disease (single or poly; HR =
1.36, 95% CI: 1.09-1.70, P < 0.01), and older age (per additional
year; HR = 1.03, 95% CI: 1.02-1.04, P < 0.01) were associated with
increased systemic ischemic events (Figure 3). No sex or race/ethnic-
ity associations were observed. Statin use was associated with
decreased systemic ischemic risk (HR = 0.82, 95% CI: 0.69-0.99,
P = 0.03) (Figure 4).
3.5 | Limb ischemic events
The 2-year rate of the composite endpoint of limb ischemic events
was 5.7%. Angioplasty and/or stenting for PAD accounted for 3.2%
of these events, peripheral bypass graft accounted for 2.1%, and
lower limb amputation accounted for 1.3% (patients could experience
more than 1 event, explaining why the total was lower than the sum
of each event). Overall, the composite outcome of systemic and limb
ischemic events was 11.9% at 2 years.
4 | DISCUSSION
This contemporary and geographically diverse study of patients with
symptomatic PAD in routine clinical practice confirmed that the
ischemic event rate remains high, with a cumulative 4-year systemic
event risk of 17.6%, mainly driven by CV mortality. The rate
increased over follow-up (~4%–5% per year), and there were no
major differences observed across the geographic regions except for
Japan, where patients experienced a lower rate of ischemic events
over time. PAD patients also experienced relatively high rates of
severe limb ischemic events (approximately 6% at 2 years, including a
1.3% rate of major amputations). Independent risk factors associated
with the increased systemic ischemic event rate were renal impair-
ment, heart failure, single or poly vascular disease, a history of MI, a
history of diabetes, and older age. Statin use was the only factor
associated with a decreased risk of recurrent ischemic events over
4 years.
The factors associated with increased ischemic events observed
in this analysis were consistent with the usual CV risk factors for
712 ABTAN ET AL.
atherosclerotic disease.2,13,14 A previous analysis of the REACH Reg-
istry9 and other studies15–18 suggested that patients with PAD do
not achieve CV risk factor control as frequently as patients with other
established atherothrombotic diseases, such as cerebrovascular dis-
ease or CV disease. In the REACH Registry, PAD patients with 3 to
5 controlled risk factors had fewer major CV events (ie, MI, stroke,
CV death) compared with PAD patients with poor control (0–2 risk
factors controlled, 2.66% vs. 3.52% 1-year rates, P = 0.17).19,20
In the present analysis, use of statin therapy was associated with
reduced risk of ischemic events. European and US guidelines recom-
mend low-density lipoprotein (LDL) cholesterol reduction in patients
at high CV risk.21,22 A previous analysis of the REACH Registry
showed a reduction of adverse limb outcomes in patients treated
with statins for symptomatic PAD as well as overall ischemic
events.23 The addition of more potent treatment regimens and more
aggressive reduction of LDL cholesterol could provide even greater
TABLE 1 Baseline patient demographics and clinical characteristics
PAD Patients Without History of Stroke /TIA
North
America,
n = 1785
Latin
America,
n = 162
Western EU,
n = 2702
Eastern
EU, n = 441
Middle
East, n = 38 Asia, n = 213
Japan,
n = 473
Total,
N = 6,005
Age, y, mean (SD) 70.44 (10.1) 68.73 (10.73) 68 (9.71) 62.92 (8.65) 66.14 (10.84) 66.22 (9.27) 72.03 (8.04) 70.52 (9.52)
Median 71.3 69.1 68.5 63.5 66.8 66.7 73.0 71.39
Range, q1–q3 63.3–78.7 62.4 –76.9 61.0–75.0 56.4–68.6 54.7–74.7 58.8–72.8 67.6–77.5 64.01–77.29
Men 1109 (62.1%) 100 (62.5%) 2057 (76.2%) 346 (78.5%) 30 (78.9%) 139 (65.3%) 394 (83.3%) 1261 (69.2%)
Diabetes 897 (50.5%) 96 (59.3%) 975 (36.4%) 152 (34.6%) 20 (52.6%) 148 (69.5%) 177 (37.4%) 855 (47.3%)
Hypertension 1540 (86.3%) 136 (84%) 2000 (74%) 325 (73.7%) 32 (84.2%) 166 (77.9%) 362 (76.5%) 1625 (89.1%)
Dyslipidemia 1437 (80.6%) 74 (45.7%) 1750 (64.8%) 237 (53.9%) 28 (73.7%) 133 (62.4%) 166 (35.1%) 1205 (66.2%)
Renal impairment 69 (4.6%) 4 (4%) 35 (1.9%) 4 (1%) 2 (7.1%) 18 (10.9%) 31 (7.9%) 53 (3.7%)
Angina
Stable angina 502 (28.7%) 28 (17.7%) 639 (23.9%) 181 (41.3%) 10 (26.3%) 47 (22.6%) 78 (16.6%) 692 (38.7%)
Unstable angina 214 (12.2%) 16 (10.1%) 195 (7.3%) 68 (15.6%) 4 (10.5%) 25 (12%) 24 (5.1%) 358 (20.1%)
Polyvascular diseasea 1072 (60.1%) 61 (37.7%) 1196 (44.3%) 260 (59%) 22 (57.9%) 97 (45.5%) 134 (28.3%) 1824 (100%)
History of MI
≤1 year 109 (6.2%) 4 (2.6%) 110 (4.1%) 41 (9.3%) 2 (5.4%) 11 (5.3%) 8 (1.7%) 122 (6.8%)
>1 year 473 (26.9%) 26 (17%) 517 (19.3%) 104 (23.6%) 10 (27%) 24 (11.6%) 43 (9.1%) 470 (26.2%)
Atrial fibrillation/flutter 218 (12.4%) 5 (3.2%) 250 (9.5%) 52 (11.9%) 2 (5.4%) 9 (4.3%) 35 (7.4%) 290 (16.3%)
Congestive heart failure 372 (21.1%) 8 (5%) 341 (12.9%) 57 (13.1%) 7 (18.4%) 27 (12.9%) 27 (5.7%) 407 (22.9%)
Obesity
Overweight, BMI,
25– > 30
677 (52.2%) 71 (74.7%) 1199 (67.5%) 178 (61.6%) 19 (65.5%) 61 (79.2%) 107 (93%) 717 (63.8%)
Class I, BMI, 30– > 35 396 (30.5%) 22 (23.2%) 460 (25.9%) 96 (33.2%) 7 (24.1%) 14 (18.2%) 8 (7%) 278 (24.7%)
Class II, BMI, 35–
> 40
145 (11.2%) 1 (1.1%) 93 (5.2%) 13 (4.5%) 2 (6.9%) 2 (2.6%) 0 (0%) 89 (7.9%)
Class III, BMI ≥40 79 (6.1%) 1 (1.1%) 24 (1.4%) 2 (0.7%) 1 (3.4%) 0 (0%) 0 (0%) 40 (3.6%)
Smoker
Former 962 (54.9%) 81 (52.3%) 1333 (51.1%) 168 (38.2%) 10 (28.6%) 85 (40.3%) 280 (61.4%) 859 (49%)
Current 395 (22.6%) 24 (15.5%) 741 (28.4%) 172 (39.1%) 14 (40%) 27 (12.8%) 98 (21.5%) 366 (20.9%)
Medication
Acetylsalicylic acid 1303 (73.1%) 125 (77.2%) 1536 (57%) 328 (74.4%) 30 (78.9%) 118 (55.4%) 166 (35.1%) 1111 (61.4%)
At least 1 antiplatelet 1456 (81.6%) 138 (85.2%) 2170 (80.4%) 383 (86.8%) 35 (92.1%) 164 (77%) 384 (81.2%) 1513 (83.2%)
Angiotensin
converting enzyme
inhibitors
815 (46%) 58 (36.3%) 1097 (40.8%) 266 (60.3%) 17 (45.9%) 65 (30.5%) 88 (18.6%) 909 (50.4%)
Angiotensin II receptor
antagonists
448 (25.4%) 30 (18.8%) 493 (18.4%) 13 (3%) 8 (21.6%) 64 (30.2%) 139 (29.4%) 360 (20.1%)
Nitrates/other anti-
angina
371 (21.4%) 22 (13.8%) 511 (19.3%) 156 (35.5%) 9 (24.3%) 52 (24.6%) 97 (20.5%) 493 (27.7%)
Statin 1371 (76.9%) 72 (44.4%) 1673 (62%) 242 (54.9%) 28 (73.7%) 134 (62.9%) 143 (30.2%) 1192 (65.5%)
β-Blockers 943 (53.1%) 35 (21.7%) 1002 (37.3%) 203 (46%) 15 (40.5%) 80 (37.6%) 60 (12.7%) 731 (40.5%)
Abbreviations: BMI, body mass index; EU, Europe; MI, myocardial infarction; PAD, peripheral artery disease; SD, standard deviation; TIA, transient ische-
mic attack.
aPolyvascular disease was defined as coexistent symptomatic (clinically recognized) arterial disease in 2 or 3 territories (coronary, cerebral, and/or periph-
eral) within each patient.
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risk reduction. One study that assessed a composite outcome of cor-
onary heart disease, cerebrovascular disease, and peripheral vascular
disease events demonstrated that both statins and ezetimibe were
associated with reductions in the risk of the composite outcome.24 In
addition, the new PCSK9 inhibitors, such as alirocumab or evolocu-
mab, showed a reduction in LDL cholesterol levels when added to
maximally tolerated statin therapy. Post hoc analyses have also sug-
gested a reduction in CV event rates in high-risk patients with estab-
lished CV disease receiving these agents,25,26 but results from
ongoing clinical trials are needed,27,28 and these agents have yet to
be assessed in the specific population of PAD patients.
Residual ischemic risk was uniformly distributed over the differ-
ent geographic areas, except for Japan, where patients experienced
lower event rates. The explanations for such differences have been
described previously.29 Briefly, differences in disease management
and medication use have been reported (in particular, the use of clo-
pidogrel is substantially higher in Japan than in other regions of the
world), which may have contributed to some extent in the improved
outcomes in Japan, supported by evidence that clopidogrel use may
be superior to aspirin in reducing major CV events in PAD
FIGURE 1 Cumulative incidence rates of primary outcome of CV
death, MI, or stroke for post-MI patients with no history of
TIA/stroke. Abbreviations: CV, cardiovascular; MI, myocardial
infarction; TIA, transient ischemic attack
FIGURE 2 Cumulative incidence rates of cardiovascular outcomes in PAD patients with no history of stroke or TIA by year of follow-up.
Abbreviations: MI, myocardial infarction; PAD, peripheral artery disease; TIA, transient ischemic attack
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patients.30,31 In addition, gaps in country-based payer policies and
healthcare systems might explain differences in risk factor prevalence
and management. Moreover, genetic susceptibilities and lifestyle dif-
ferences may also play a role in risk variation.29 Nevertheless, residual
risk remains high, and events accrued progressively over time across
all geographic areas.
Antiplatelet agents are a cornerstone of the treatment of athero-
thrombotic disease. Patients with previous stroke or TIA were
excluded from the present analysis, as they present a specific risk-to-
benefit balance of antithrombotic use.10 However, antiplatelet agents
were not associated with a statistically significant reduction in risk of
systemic ischemic events in the present analysis. This may be related
to the relatively lower efficacy of aspirin compared with clopidogrel
or other antiplatelet agents in patients with PAD,32,33 the high pro-
portion of patients in the REACH Registry receiving aspirin as the
antiplatelet agent, or that the analysis was not powered to show sta-
tistical significance.
More intensive antiplatelet treatment strategies might provide
additional benefit in patients with PAD. A post hoc analysis of data
from the CHARISMA (Clopidogrel for High Atherothrombotic Risk and
Ischemic Stabilization, Management, and Avoidance) trial in a sub-
group of patients diagnosed with PAD showed a trend for a benefit of
clopidogrel plus aspirin over aspirin alone in this population, with a
reduction in MI rates.19,34 At the time the REACH Registry was estab-
lished, the novel oral antithrombotic agents prasugrel, ticagrelor, vora-
paxar, or rivaroxaban were not available. Therefore, the present
analysis cannot provide insights on the benefit of those agents.
Results of the EUCLID (Examining Use of tiCagreLor In paD) trial,
which compared monotherapy with ticagrelor or clopidogrel in PAD
patients without indication for dual antiplatelet therapy, did not show
a reduction in composite ischemic or limb events or in major bleeding,
although a reduction in ischemic stroke was observed.35 Of note,
patients who were homozygous for loss of function alleles to clopido-
grel were excluded, though this exclusion did not seem to be the
FIGURE 3 Hazard ratio for the primary
outcome of cardiovascular death, MI, or
stroke for post-MI patients with no history
of TIA/stroke according to geographic
regions after adjustment with the REACH
risk score. Abbreviations: CI, confidence
interval; CV, cardiovascular; HR, hazard
ratio; MI, myocardial infarction; NA, not
applicable; TIA, transient ischemic attack
FIGURE 4 Hazard ratios of determinants
for the primary outcome of CV death,
nonfatal MI, and nonfatal stroke estimated
by multivariate Cox models in PAD
patients with no history of TIA/stroke.
Abbreviations: ACE, angiotensin-converting
enzyme; CI, confidence interval; CV,
cardiovascular; EU, Europe; HR, hazard
ratio; MI, myocardial infarction; PAD,
peripheral artery disease; TIA, transient
ischemic attack; US, United States
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cause of the overall neutral results for ticagrelor versus clopidogrel.
Therefore, all patients included in the EUCLID trial were receiving
effective antiplatelet therapy.35
The use of a dual antiplatelet therapy rather than a single anti-
platelet therapy might provide additional benefit for PAD patients.
A subgroup analysis of the PLATO (Study of PLATelet inhibition and
patient Outcomes) trial showed that the benefit of ticagrelor over
clopidogrel in acute coronary syndrome patients was consistent in
the subgroup of PAD patients compared with the global popula-
tion.36 A similar analysis from the post-MI PEGASUS (PEGASUS-
TIMI 54) trial also showed a consistent benefit of ticagrelor over
placebo in addition to aspirin in post-MI patients with PAD.37,38
Similarly, a recent analysis from the DAPT (The Dual Antiplatelet
Therapy Study) trial showed clear benefit of prolonged dual antipla-
telet therapy in PAD patients treated with coronary stents.39
Recently, vorapaxar, a PAR1 platelet receptor antagonist has been
evaluated in addition to aspirin in the TRA 2P –TIMI 50 (Thrombin
Receptor Antagonist in Secondary Prevention of Atherothrombotic
Ischemic Events) trial in a secondary prevention setting in patients
with stable atherosclerosis (defined as prior MI or stroke within the
previous 2 weeks to 12 months prior to randomization) or PAD
(defined as claudication and abnormal ABI or prior revasculariza-
tion). In that trial, vorapaxar demonstrated a reduction in ischemic
events at 3 years, including hospitalization for acute limb ischemia
and peripheral revascularization.40 Another strategy to increase
antithrombotic intensity could be the addition of an anticoagulant
to aspirin. The COMPASS (Cardiovascular OutcoMes for People
Using Anticoagulation StrategieS) trial (NCT01776424) assesses the
effect of the addition of rivaroxaban to aspirin versus rivaroxaban
alone or aspirin alone in patients with established CAD or PAD, and
will provide information regarding potential benefits and risks of this
approach.
There are some limitations to the present analysis. The collection
of limb events and systemic events was not done in the exact same
method, and there was no assignment of a precise date for limb
events. Additionally, limb events were tracked on a declarative basis
at the end of follow-up, leading to some missing data at the 4-year
time point. Consequently, our analysis was underpowered to deter-
mine risk factors for these occurrences. These analyses are drawn
from an observational registry; the results presented here are there-
fore descriptive, and analyses on the determinants of residual risk as
well as analyses on geographic differences must be interpreted cau-
tiously. Clinical events were not adjudicated in the REACH Registry,
but measures were taken to select high-quality physicians, and diag-
noses were provided by hospitals and doctors based on their exper-
tise. Patient adherence to medication was not captured in the
registry, and adherence could impact patient outcomes. Finally,
although the data were taken from a large cohort, the analysis may
have been underpowered for some comparisons.
5 | CONCLUSION
This analysis of the REACH Registry showed an important ischemic
risk in patients with PAD, continuously increasing over the 4 years of
follow-up and mainly driven by CV mortality. Limb ischemic events
represent a substantial additional burden to that related to systemic
ischemic events in this population. Secondary prevention strategies,
including enhanced antithrombotic treatment and more intense lipid
lowering, may be useful to improve prevention of ischemic and limb
vascular events in this high-risk population.
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